A Phase 2 interventional study of Rilzabrutinib dose 1 and Rilzabrutinib dose 2 in Graves' Disease, sponsored by Sanofi. Recruiting at 24 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Graves Disease with a site in Italy — 6 open to participants now, 9 under way, 1 of them phase 3. Graves Disease · Italy.
Among the 14 studies in Graves Disease with a site in Italy, this one is the 10th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2025, is one of 5 in phase 2, and was the 10th registered.
162 studies on the registry are indexed under Graves Disease; 53 are open to participants now.
Browse Graves Disease studies →6 of the 14 studies in Graves Disease with a site in Italy are open now. Recruiting first, the newest first:
argenx · Sites in Italy, Belgium, Bulgaria and 11 more countries
Ages 18+
Immunovant Sciences GmbH · Sites in Italy, United States, Australia and 15 more countries
Ages 18–75
Immunovant Sciences GmbH · Sites in Italy, United States, Belgium and 7 more countries
Ages 18–75
IRCCS Ospedale San Raffaele · Sites in Italy
Ages 2–18
University of Padova · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 39 Graves Disease studies recruiting now, 17 (44%) set no upper age limit and 20 (51%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 6 · Phase 3 1
First in 2014; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 104 interventional studies indexed under Graves Disease.
Median enrollment 60 across the 11 interventional studies, 100 across the 3 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 1 study filed under Graves Disease — fewer than ten, so there is no comparison to draw.
2 of the studies in Graves Disease with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06984627SanofiA Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease | 2027-02-11 |
| NCT07018323Immunovant Sciences GmbHA Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Graves Disease with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a parallel group, Phase 2, 2-arm study to measure the treatment effect and safety of rilzabrutinib dose 1 or rilzabrutinib dose 2 in participants with Graves' disease, with and without Graves' orbitopathy, aged 18 years or older.
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Rilzabrutinib
Drug: Rilzabrutinib dose 1
Rilzabrutinib
Drug: Rilzabrutinib dose 2
Pharmaceutical form:Tablet-Route of administration:Oral
Also known as: SAR444671
Pharmaceutical form:Tablet-Route of administration:Oral
Also known as: SAR444671
Percent change from baseline in FT4 levels
Free thyroxine
Time frame: At Week16
Percent change from baseline in FT3 levels
Free triiodothyronine
Time frame: At Week16
Proportion of participants with FT4 levels within normal limits
Time frame: At Week16
Proportion of participants with FT3 levels within normal limits
Time frame: At Week16
Incidence of treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) and withdrawals due to TEAEs during the study period
Time frame: Up to week 20
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Sep 2025 (actual). Primary completion is estimated for Feb 2027, 17 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Aug 2026 → Feb 2027 and completion Sep 2026 → Mar 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rilzabrutinib